Trial reportPloS one2016
Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier.
Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 119 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme
(Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)
Who cites it
119 citing papers in PubMed, 3 syntheses or guidelines pooled it, 205 citations in OpenAlex.
- Therapeutic modulation of the blood-brain barrier in brain tumors: a systematic review of clinical and translational approaches.Cancer chemotherapy and pharmacology · 2026Pooled it
- Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art.Frontiers in oncology · 2022Pooled it
- Laser interstitial thermal therapy and adjuvant pembrolizumab in recurrent high-grade astrocytoma: a Phase 1/randomized Phase 2b trial.Nature communications · 2026Trial
- Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Trial
- A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Trial
- Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Imaging, histological, and molecular characterization of a preclinical, orthotopic model of recurrent glioblastoma following image-guided laser ablation of the primary tumor.Journal of neurosurgery · 2026Article
- Laser interstitial thermal therapy enhances bidirectional blood-brain barrier permeability in glioblastoma.Neuro-oncology · 2026Article
- Butterfly gliomas: to biopsy or to ablate - a longitudinal cohort study.Journal of neuro-oncology · 2026Article
- Laser interstitial thermal therapy versus stereotactic radiosurgery for first-time treatment of recurrent glioblastoma: a retrospective single-center study.Journal of neuro-oncology · 2026Article
- Review
- Same-session hybrid surgery for multifocal glioblastoma: integrating open resection with laser interstitial thermal therapy. Illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives.iScience · 2026Review
- Automated laser retraction for targeted glioblastoma coverage during laser interstitial thermal therapy.Medical physics · 2026Article
- Laser interstitial thermal therapy for IDH wild-type recurrent glioblastoma: a Scandinavian two-center cohort study.Acta neurochirurgica · 2026Article
- Modulating the glioma microenvironment with laser interstitial thermal therapy: mechanisms and therapeutic implications.Journal of neuro-oncology · 2025Review
- Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Volumetric and diffusion MRI longitudinal patterns in brain metastases after laser interstitial thermal therapy.European radiology · 2025Article
- Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPoor central nervous system penetration of cytotoxic drugs due to the blood brain barrier (BBB) is a major limiting factor in the treatment of brain tumors. Most recurrent glioblastomas (GBM) occur within the peritumoral region. In this study, we describe a hyperthemic method to induce temporary disruption of the peritumoral BBB that can potentially be used to enhance drug delivery.
methodsTwenty patients with probable recurrent GBM were enrolled in this study. Fourteen patients were evaluable. MRI-guided laser interstitial thermal therapy was applied to achieve both tumor cytoreduction and disruption of the peritumoral BBB. To determine the degree and timing of peritumoral BBB disruption, dynamic contrast-enhancement brain MRI was used to calculate the vascular transfer constant (Ktrans) in the peritumoral region as direct measures of BBB permeability before and after laser ablation. Serum levels of brain-specific enolase, also known as neuron-specific enolase, were also measured and used as an independent quantification of BBB disruption.
resultsIn all 14 evaluable patients, Ktrans levels peaked immediately post laser ablation, followed by a gradual decline over the following 4 weeks. Serum BSE concentrations increased shortly after laser ablation and peaked in 1-3 weeks before decreasing to baseline by 6 weeks.
conclusionsThe data from our pilot research support that disruption of the peritumoral BBB was induced by hyperthemia with the peak of high permeability occurring within 1-2 weeks after laser ablation and resolving by 4-6 weeks. This provides a therapeutic window of opportunity during which delivery of BBB-impermeant therapeutic agents may be enhanced.
trial registrationClinicalTrials.gov NCT01851733.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.